Genworth Financial, Inc. (GNW - Free Report) delivered third-quarter 2018 adjusted operating income of 29 cents per share, which beat the Zacks Consensus Estimate of 23 cents by 26.1%. The bottom line also soared 93.3% from the year-ago quarter’s tally.
Genworth Financial, Inc. Price, Consensus and EPS Surprise
The reported quarter benefited from a strong performance at the mortgage businesses.
Total revenues of Genworth Financial were $2.1 billion, flat year over year. However, the top line missed the Zacks Consensus Estimate by 0.7%.
Net investment income grew 2.3% year over year to $815 million on higher investment yields.
Total benefits and expenses declined 3.1% year over year to $1.9 billion, primarily owing to lower benefits and other changes in policy reserves, Interest credited, acquisition and operating expenses plus interest expense.
U.S. Mortgage Insurance: Adjusted operating income of $118 million soared nearly 61.6% year over year. Loss ratio improved 900 bps year over year to 11%. The third quarter benefited from a lower corporate tax rate and higher premiums from an increase in insurance in force.
Canada Mortgage Insurance: Adjusted operating income was $44 million, up 18.9% year over year. Loss ratio remained flat year over year at 14% as less favorable loss reserve development offset lower new delinquencies.
Australia Mortgage Insurance: Adjusted operating income of $17 million improved 41.7% year over year. Loss ratio improved 60 bps year over year to 28%, driven by an increase in earned premiums and a favorable loss performance.
U.S. Life Insurance: Adjusted operating loss came in at $3 million, wider than year-ago loss of $1 million due to higher loss at Long Term Care Insurance. However, this was partially offset by lower loss at Life Insurance and an improved income at Fixed Annuities.
Runoff: Adjusted operating income of $14 million was up 7.7% year over year, aided by lower taxes.
Corporate and Other: Adjusted operating loss came in at $45 million, narrower than the year-ago loss of $58 million.
Genworth Financial exited the quarter with cash, cash equivalents and invested assets of $73.2 billion, down 4.8% from the level at year-end 2017.
Long-term borrowings of Genworth Financial totaled $4 billion as of Sep 30, 2018, down 4.1% from the tally at 2017 end.
Book value per share (excluding accumulated other comprehensive income) was $21.43 as of Sep 30, 2018, having increased 6.6% from the year-ago quarter’s figure.
On Oct 26, 2018, the Delaware Department of Insurance announced that it has scheduled a public hearing on Nov 28, 2018 on the pending acquisition of Genworth Life Insurance Company (GLIC) by entities affiliated with Oceanwide.
Genworth and Oceanwide also announced that the parties agreed that Genworth Holdings will contribute a total of $175 million to GLIC in three phases — by the end of March 2019, by the end of September 2019 and by the end of January 2020.
In the mean time, Oceanwide and Genworth Financial are developing a new capital investment plan whereby Oceanwide would contribute an aggregate of $1.5 billion to Genworth Financial over time following the closing of the transaction. The contribution would be used to further improve Genworth Financial's financial stability, which might include retiring its debt due in 2020 and 2021 or enabling future growth opportunities.
Genworth Financial carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Performance of Other Life Insurers
Among other players from the life insurance industry having already reported third-quarter earnings, the bottom line of Torchmark Corporation , Reinsurance Group of America, Incorporated (RGA - Free Report) and Health Insurance Innovations, Inc. (HIIQ - Free Report) exceeded the respective Zacks Consensus Estimate.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>